Magnitude of end-stage renal disease in IDDM: a 35 year follow-up study

Kidney International
M KrolewskiJames H Warram

Abstract

Significant improvements were made during the last two decades in the treatment of IDDM patients. To assess the risk of ESRD in a population that was exposed to these improvements, we determined the cumulative incidence of ESRD in a cohort of 142 white patients who were aged less than 21 years when they came to the Joslin Diabetes Center in 1959 with recently diagnosed IDDM. The first case of ESRD occurred after 13 years of IDDM, and a total of 25 cases have developed by 35 years' duration (cumulative incidence 21.3%). Median survival after the diagnosis of ESRD for the 16 patients who began dialysis was only 3.5 years. A strong predictor of the development of ESRD was the level of glycemic control during the first two decades of IDDM. ESRD developed in 36.3% of patients in the worst tertile for glycemic control but only in 14.4% and 9.2% of those in the middle and best tertiles. In comparison with two population based studies, the onset of ESRD in the Joslin Cohort was postponed by about five years. This advantage is more plausibly attributable to differences arising after the diagnosis of diabetes than to referral of less severe cases of IDDM to the Joslin Diabetes Center. What differences in diabetes care accounted for the p...Continue Reading

References

Jan 1, 1992·Statistical Methods in Medical Research·P K Andersen
Oct 1, 1992·Journal of the American Society of Nephrology : JASN·J E SiegelM C Weinstein
Oct 19, 1989·The New England Journal of Medicine·C C CowieV M Hawthorne
Jan 1, 1989·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·S TeutschP Eggers
Sep 20, 1973·The American Journal of Cardiology·A R Christlieb
May 11, 1995·The New England Journal of Medicine·A S KrolewskiJ H Warram
Jan 6, 1994·The New England Journal of Medicine·M BojestigJ Ludvigsson
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Dec 16, 1995·BMJ : British Medical Journal·B A Kiberd, K K Jindal

❮ Previous
Next ❯

Citations

Dec 1, 2005·Current Diabetes Reports·Bruce A Perkins, Andrzej S Krolewski
Feb 8, 2008·Current Diabetes Reports·Matthew D BreyerRaymond C Harris
Jul 28, 2010·Current Diabetes Reports·Alexander C Wiseman
Dec 17, 2008·Biochemical and Biophysical Research Communications·Hikari SuzukiMasakiyo Sasahara
Jul 29, 2005·The American Journal of Pathology·Akari InadaYutaka Seino
May 1, 2012·Diabetes Technology & Therapeutics·David M Maahs
Jun 8, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S K MakA K Wong
Dec 20, 2007·Current Opinion in Nephrology and Hypertension·Matthew D BreyerRaymond C Harris
Feb 9, 2012·Current Opinion in Nephrology and Hypertension·Merlin C ThomasKarl Tryggvason
Jul 15, 2005·Kidney International·Kojiro NagaiHidenori Arai
Aug 10, 2012·American Journal of Physiology. Renal Physiology·Harmeet KaurIshwarlal Jialal
May 28, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Sridevi DevarajIshwarlal Jialal
Feb 7, 2014·Diabetology & Metabolic Syndrome·Anselmo J Mc Donald PAlberto Cumbrera O
Jun 6, 2008·Journal of the American Society of Nephrology : JASN·Yukio YuzawaSeiichi Matsuo
Feb 8, 2008·Journal of the American Society of Nephrology : JASN·Pawel P WolkowAndrzej S Krolewski
Feb 15, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Elizabeth T RosolowskyAndrzej S Krolewski
Jun 28, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Rimei NishimuraUNKNOWN Allegheny County Registry
Nov 13, 2013·Clinical and Experimental Nephrology·Andrzej S KrolewskiMonika A Niewczas
Jan 5, 2002·Expert Opinion on Investigational Drugs·S VasanH W Founds
Nov 26, 2014·Proceedings of the National Academy of Sciences of the United States of America·Tony JourdanGeorge Kunos
Aug 27, 2015·Diabetes·Jennifer N ToddJose C Florez
May 2, 2014·Advances in Chronic Kidney Disease·Valma Harjutsalo, Per-Henrik Groop
May 2, 2014·Advances in Chronic Kidney Disease·Amy Jayne McKnightAlexander P Maxwell
Oct 16, 2012·Seminars in Nephrology·Andrzej S Krolewski, Joseph V Bonventre
Dec 6, 2011·Maturitas·Ronald PyramLisel Loney-Hutchinson
Oct 22, 2011·Diabetes Research and Clinical Practice·Wen-Jin FuQian Wang
Jul 19, 2011·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Miwa MoritaYasuhiko Iwamoto
Feb 9, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Elizabeth F O KernMiriam F Weiss
Nov 26, 2008·Journal of Proteomics·Yannick BrunnerJean-Charles Sanchez
Oct 14, 2008·Diabetes Research and Clinical Practice·Elizabeth T RosolowskyAndrzej S Krolewski
Apr 10, 2007·Seminars in Nephrology·Matthew D BreyerRaymond C Harris
Jan 10, 2006·The American Journal of Pathology·Tomoki KosugiKenji Kadomatsu
Sep 14, 2007·Pediatric Diabetes·Lorenzo PasqualiSteven Ringquist
Aug 20, 2015·Saudi Journal of Biological Sciences·Badr A AldahmashMahmoud S Metwaly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.